RCT: Efficacy of Ipilimumab vs. FOLFOX in combination with Nivolumab and Trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma.

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Commentary: AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma – JAMA Oncology (free for a limited period)